Price To Earnings Ratio 99.93 | Sector PE 71.67 |
PB Ratio 11.78 | Sector PB 9.22 |
EPS 60.38 | Dividend Yield 0.87 |
Today's Volume 558.728 K | 5 Day Avg. Volume 807.321 K |
PEG Ratio -8.14 | Market Cap. ₹ 1,60,000.00 Cr. |
Time | DIVISLAB | VS | Industry |
---|---|---|---|
1 Day | 0.28% | -1.57% | |
1 Week | -0.57% | -0.71% | |
1 Month | 5.92% | -0.68% | |
6 Months | 28.25% | 19.22% | |
1 Year | 60.31% | 40.44% |
Period (Days) | SMA | Indication |
---|---|---|
10 | 6037.27 | Bearish |
20 | 5909.02 | Bullish |
30 | 5861.22 | Bullish |
50 | 5784.29 | Bullish |
100 | 5380.09 | Bullish |
200 | 4696.93 | Bullish |
Annual | FY 2024 | FY 2023 | FY 2022 | ||||
---|---|---|---|---|---|---|---|
Operating Activities | 1261.00 | 2459.00 | 1911.80 | ||||
Investing Activities | -269.00 | -2707.00 | -2194.92 | ||||
Financing Activities | -799.00 | -797.00 | -532.44 | ||||
Net Cash Flow | 193.00 | -1045.00 | -815.56 |
All Figures in ₹ Cr., unless mentioned otherwise
Name | 1D (%) | 1W (%) | 1M (%) | 6M (%) | 1Y (%) |
---|---|---|---|---|---|
Divi's Laboratories | 0.28 | -0.57 | 5.92 | 28.25 | 60.31 |
Alembic | -0.87 | 4.08 | 1.29 | 2.51 | 2.51 |
Aurobindo Pharma | 1.41 | -0.57 | -10.08 | -10.84 | 14.22 |
Fortis Healthcare | 2.64 | 7.72 | 17.12 | 47.18 | 78.55 |
Ajanta Pharmaceuticals | -1.34 | -5.51 | -8.71 | 12.47 | 38.64 |
Divi's Laboratories Limited is an Indian company that manufactures and markets active ingredients (APIs), intermediates and nutrients for export. The company's products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to its generic business, the Company supports pharmaceutical companies through custom synthesis businesses in the commercialization of their proprietary products, from gram-scale requirements for clinical trials to launch and late life cycle management. The company's subsidiaries are Divis Laboratories (USA) Inc and Divi's Laboratories Europe AG.